Science for Society: CRISPR and the Future of Genome Editing
Science for Society: CRISPR and the Future of Genome Editing
Scientific breakthroughs often change not only what happens in the lab, but also the world around us. One of the most exciting advances in recent years is CRISPR, a technology that allows scientists to precisely edit genes—the instructions in our DNA that determine how living things grow and function. From treating genetic diseases to improving crops, CRISPR is opening new possibilities in science and medicine.
At the same time, powerful technologies raise important questions. How can gene editing be used safely and responsibly? Who will benefit from these advances? And how can we ensure that innovations like CRISPR serve society as a whole?
The German Center for Research and Innovation (DWIH) San Francisco invites you to the second edition of Science for Society, bringing together experts from research and industry to explore the promise and challenges of genome editing and its impact on society.
The event will bring together distinguished representatives from the international diplomatic corps, including Spanish Consul General Carlos Medina Drescher, who will deliver welcoming remarks, Deputy Consul General Laura Muniozguren, and Dr. Beate Antonich, Senior Advisor for Science and Technology at the German Consulate General in San Francisco.
What We Will Discuss
- The conversation will explore the scientific, societal, and ethical dimensions of genome editing, including questions such as:
- How is CRISPR changing medicine and our understanding of genes?
- What does genome editing mean for everyday people and society as a whole?
- How can we balance the possibilities of CRISPR with ethical and safety concerns?
- How can these technologies be developed responsibly and fairly?
- Why is international collaboration important for science and society?
Program
4:30 – 5:00 PM – Arrival and Welcome
5:00 – 5:45 PM – Moderated Discussion
5:45 – 6:15 PM – Audience Q&A
6:15 PM – 7:00 PM – Networking Reception
Date: April 22, 2026
Location: German Hub San Francisco
Isabel Esain GarciaIsabel Esain Garcia is a postdoctoral researcher in the laboratory of Jennifer Doudna at University of California, Berkeley, where her research focuses on understanding gene regulation and exploring how genome editing technologies can help address complex diseases. She earned her PhD at the University of Cambridge, where she studied the role of specific DNA structures in controlling gene expression and their links to cancer biology. Her doctoral work was recognized with the Cancer Research UK Cambridge Institute PhD Thesis Prize. Combining expertise in molecular biology and CRISPR-based approaches, her research aims to uncover fundamental mechanisms of gene regulation and identify new possibilities for therapeutic intervention.
Thomas WechslerThomas Wechsler is a gene therapy consultant and an experienced leader in the gene therapy sector, working at the intersection of biotechnology, clinical development, and strategic advisory. Over the course of his career, he has collaborated with biotechnology startups, academic research groups, and major pharmaceutical companies to advance innovative gene therapies for rare and common diseases. His work spans the full development pipeline—from early research and preclinical studies to clinical trials and regulatory strategy—supporting treatments targeting metabolic disorders, inherited eye diseases, and neurological conditions. Through his consulting work, Wechsler helps organizations translate scientific discoveries into therapies that can reach patients.
Event Information
April 22, 2026, 4:30 PM to 7:30 PM
German Hub San Francisco, 101 Montgomery Street, 14th floor, San Francisco, CA 94104
Organizer(s): German Center for Research and Innovation (DWIH)